Buzz Benson
Chairman of the Board

Mr. Benson has served as a director of our company since 2001 and as chairman of the board since June 2011. Mr. Benson is a managing director and president of SightLine Partners LLC, a venture capital firm that invests in emerging growth medical technology companies. SightLine Partners was formed in 2004 to acquire the healthcare venture capital funds of Piper Jaffray Ventures.

Prior to co-founding SightLine Partners, he was a Managing Director and President of Piper Jaffray Ventures from 1992 to 2004. From 1986 to 1992, he was co-head of the Piper Jaffray healthcare investment banking group. Prior to joining Piper Jaffray in 1986, Mr. Benson was a partner at Stonebridge Capital, a partnership investing in emerging publicly traded companies. Previously, he was an investment officer with Cherry Tree Ventures and a manager in the public accounting firm of Arthur Andersen & Co. Mr. Benson holds a B.S. degree in accounting from St. John’s University and is a Certified Public Accountant.
 

Charles A. Sanders, M.D.
Independent Director and Chairman Emeritus

Dr. Sanders has served as a director of our company since 2001 and served as chairman of the board from 2002 to June 2011. He currently serves as an independent director and chairman emeritus of our board of directors. Dr. Sanders is retired from Glaxo, Inc. (now GlaxoSmithKline), a pharmaceutical company, where he served as chief executive officer from 1989 to 1994 and chairman of the board from 1992 to 1995. Before joining Glaxo, Dr. Sanders spent eight years with Squibb Corp., where he held a number of posts, including the positions of vice chairman, chief executive officer of the science and technology group and chairman of the science and technology committee of the board of directors.

Previously, Dr. Sanders was general director of Massachusetts General Hospital and professor of medicine at Harvard Medical School. Dr. Sanders is a director of Icagen, Inc., BioCryst Pharmaceuticals, Inc. and Biodel Inc. Within the last five years, Dr. Sanders has also served as a director of Cephalon, Inc., BioPure Corporation, Trimeris, Inc., Genentech, Inc., Fisher Scientific International, Inc., and Vertex Pharmaceuticals Incorporated. He is currently a member of GlaxoSmithKline Foundation, the Institute of Medicine of the National Academy of Sciences, a member of the CSIS Board of Trustees, chairman of Project HOPE and chairman of the Foundation for the National Institutes of Health. Dr. Sanders is also a past chairman of the New York Academy of Sciences, past chairman of The Commonwealth Fund, past chairman of the University of North Carolina Healthcare System, and past chairman of the Overseers Committee to Visit the Harvard Medical School.

Dr. Sanders received his M.D. degree from Southwestern Medical College of the University of Texas.
 

Richard O. Brajer
President and Chief Executive Officer

Mr. Brajer joined LipoScience, Inc. on February 26, 2003. He serves as President and CEO and is a member of the Board of Directors. Mr. Brajer joined LipoScience from Becton Dickinson and Company where he served as Corporate Executive Officer and President for the company's $1.2 billion sales worldwide diagnostic business. He began his 12-year career with BD in 1990 as director of corporate planning and subsequently held a number of general management positions in the United States and Europe. He was elected a corporate officer of Becton Dickinson in 1998.

Prior to joining Becton Dickinson, Mr. Brajer served as a consultant with McKinsey & Company from 1987 to 1990. At McKinsey, he worked with client executives to solve problems and develop action plans on issues relating to marketing, operations, organization and strategy. Mr. Brajer began his career as a product development engineer with the Procter & Gamble Company. He received the degree of Bachelor of Science in Chemical Engineering from Purdue University. He also holds a Master of Business Administration from Stanford University.
 

Robert J. Greczyn, Jr.
Director

Mr. Greczyn has served as a director of our company since March 2011. From 2000 to 2010, he was the chief executive officer of Blue Cross Blue Shield of North Carolina, where he also served on the board of the Blue Cross Blue Shield Association and chaired several committees. From 2006 to 2008, Mr. Greczyn was chairman of the board of the Council for Affordable Quality Care, an alliance of chief executive officers of the nation’s leading health insurers working to simplify healthcare transactions. Mr. Greczyn received an M.P.H. degree in health policy from the University of North Carolina at Chapel Hill and a B.A. degree in psychology from East Carolina University.
 

Christopher W. Kersey
Director

Dr. Kersey has served as a director of our company since 2009. He currently serves as a managing member of Camden Partners Holdings, LLC, a venture capital firm focusing on the healthcare and life science industries, which he joined in 2008. From December 2009 to July 2010, he served on the board of directors of Pet DRx Corporation, a provider of veterinary care services. He also serves on the board of trustees of The Johns Hopkins University School of Medicine and the board of trustees of The Johns Hopkins Hospital. From 2006 to 2008, Mr. Kersey was the chief business development officer and chief medical officer of RediClinic LLC, an operator of retail-based medical clinics. Prior to joining RediClinic, he served as a managing director from 2002 to 2006 of Cogene Ventures, a healthcare and life science late-stage venture capital fund.

Mr. Kersey began his career in 1998 as an associate at Menlo Ventures, where he focused on healthcare and life science investments. His clinical research background includes fellowships at the National Institutes of Health and the Emory University School of Medicine, where he focused on molecular biology and cardiovascular surgery, respectively. Mr. Kersey received a B.A. degree from Stanford University, an M.D. degree from the Emory University School of Medicine and an M.B.A. degree from Harvard Business School.
 

John H. Landon
Director

Mr. Landon has served as a director of our company since 2007. Mr. Landon served as the vice president and general manager of Medical Products for E.I. DuPont de Nemours and Company, or DuPont, from 1992 until his retirement in 1996. Prior to that, Mr. Landon served in various capacities at DuPont, including vice president and general manager, diagnostics and biotechnology from 1990 to 1992, director of diagnostics from 1988 to 1990, business director of diagnostic imaging from 1985 to 1988 and in various other professional and management positions from 1962 to 1985. Mr. Landon served as chairman of the board of Cholestech Corporation prior to its 2007 sale to Inverness Medical and as a director of Digene Corporation prior to its 2007 sale to QIAGEN.

He currently is a member of the board of AspenBio Pharma, Inc., a publicly held pharmaceutical company, a trustee and member of the governance committee of Christiana Care Health System, a diversified healthcare delivery company, and a member of the advisory board of Water Street Health Care Partners. Mr. Landon received a B.S. degree in chemical engineering from the University of Arizona.
 

Daniel J. Levangie
Director

Mr. Levangie has served as a director of our company since November 2010. He currently serves as CEO of Dune Medical. He is also a Principal and Managing Partner at Constitution Medical Investors, a private equity firm focused on the healthcare sector. Previously, Mr. Levangie served as president, chief executive officer and a director of Keystone Dental, a dental implant device company, from 2009 until March 2011 and is currently chairman. From 2008 to 2009, he served as executive vice president of Cytyc Corporation, a medical equipment and device company targeting women’s health and cancer, and president of Cytyc Surgical Products, a wholly-owned subsidiary of Cytyc, from July 2006 until the acquisition of Cytyc by Hologic, Inc. in October 2007. Prior to July 2006, Mr. Levangie held several positions with Cytyc, including executive vice president and chief commercial officer from 2004 to 2006, chief executive officer and president of Cytyc Health Corporation from 2002 to 2003 and executive vice president and chief operating officer from 2000 to 2002. Prior to joining Cytyc in 1994, Mr. Levangie was employed in several sales and marketing positions by Abbott Laboratories, a diversified healthcare company.

Mr. Levangie is a director of Exact Sciences Corp., a publicly held diagnostics company and a director of Insulet, a publicly held medical device company. He previously held director positions at ev3, Inc., Cytyc and Hologic. Mr. Levangie received a B.S. degree in pharmacy from Northeastern University.
 

Dr. Woodrow A. Myers, Jr.
Director

Dr. Myers has served as a director of our company since March 2011. He has served as managing director of Myers Ventures LLC, a healthcare and education consulting company, since December 2005. He was the executive vice president and chief medical officer of WellPoint, Inc., a commercial health benefits company, from 2000 to 2005. From 1995 to 2000, Dr. Myers also served as the director of healthcare management at the Ford Motor Company. Dr. Myers currently serves as a director of Express Scripts, Inc. and Genomic Health, Inc. and serves as the chairman of the board of the Mozambique Healthcare Consortium. In addition, Dr. Myers has served as a director of other public companies within the last five years, including ThermoGenesis Corp. from June 2006 to December 2009 and CardioNet, Inc. from August 2007 to May 2009.

He is a former health commissioner for New York City and the State of Indiana, past chairman of the visiting committee for the Harvard School of Public Health and has served as a member of the Harvard University Board of Overseers and the Stanford University Board of Trustees. Dr. Myers holds a B.S. degree in biological sciences from Stanford University, an M.D. degree from Harvard Medical School and an M.B.A. degree from the Stanford Graduate School of Business.
 

Roderick A. Young
Director

Mr. Young has served as a director of our company since 2008. Mr. Young has been a venture partner of Three Arch Partners since May 2006. He served as a director of North American Scientific, Inc., a publicly held medical device company, from 2006 to 2009. From 2003 to 2005, Mr. Young was president and chief executive officer of Vivant Medical, Inc., a venture-backed medical device company that was acquired by Tyco International, Ltd. Prior to his tenure at Vivant, Mr. Young was president and chief executive officer of Targesome, Inc., a biotechnology company, from 1998 to 2002.

Prior to Targesome, Mr. Young also served as chairman and chief executive officer of General Surgical Innovations, a medical device company; president and chief executive officer of Focus Surgery; president of Toshiba America MRI; and president and chief operating officer of Diasonics. Mr. Young received a B.S. degree in industrial engineering from Stanford University and an M.B.A. degree from Harvard Business School.

 

Richard O. Brajer
President and Chief Executive Officer

Mr. Brajer joined LipoScience, Inc. on February 26, 2003. He serves as President and CEO and is a member of the Board of Directors. Mr. Brajer joined LipoScience from Becton Dickinson and Company where he served as Corporate Executive Officer and President for the company's $1.2 billion sales worldwide diagnostic business. He began his 12-year career with BD in 1990 as director of corporate planning and subsequently held a number of general management positions in the United States and Europe. He was elected a corporate officer of Becton Dickinson in 1998.

Prior to joining Becton Dickinson, Mr. Brajer served as a consultant with McKinsey & Company from 1987 to 1990. At McKinsey, he worked with client executives to solve problems and develop action plans on issues relating to marketing, operations, organization and strategy. Mr. Brajer began his career as a product development engineer with the Procter & Gamble Company. He received the degree of Bachelor of Science in Chemical Engineering from Purdue University. He also holds a Master of Business Administration from Stanford University.

 

 

Tom Clement
Vice President of Regulatory and Quality Affairs

Mr. Clement has served as our Vice President of Regulatory and Quality Affairs since February 2011. From January 2009 to January 2011, he served as Vice President of Global Regulatory and Clinical Affairs for QIAGEN N.V., a provider of sample and assay technology. From 2002 to 2008, Mr. Clement was Vice President of Quality and Regulatory Affairs for Roche Molecular Systems. From 1989 to 2002, he was Director of Regulatory Affairs for Organon Teknika Corporation. From 1988 to 1989, he served as Manager of Regulatory Affairs for Amersham, and from 1984 to 1988, he was Manager of Quality for Biotech Research Laboratories. Mr. Clement received a B.S. degree in business administration from the University of Maryland.

 

 

Tim J. Fischer
Chief Operating Officer

Mr. Fischer joined LipoScience in 2010 as Vice President of Research and Development and assumed the role of Chief Operating Officer in January, 2012. Prior to joining LipoScience, he served as Vice President of Development for the women's health and cancer business at Becton Dickinson and as the Vice President of Product Development for TriPath Oncology prior to the acquisition of TriPath by BD. Mr. Fischer has been in the IVD industry for the past 25 years in the fields of hematology, oncology and pathology, with extensive experience in the design, development and commercialization of over 90 products. He is a recognized leader in the IVD field with over 35 patents and numerous publications. Mr. Fischer has a Bachelor of Science degree in Biology from Indiana University.

 

 

Bob Honigberg
Vice President of Medical Affairs and Chief Medical Officer

Dr. Honigberg has served as our Vice President of Medical Affairs and Chief Medical Officer since October 2011. From 2009-2011 he served as the Chief Medical Officer, Research & Measurement for URAC, an accreditation commission in Washington, D.C., and as a consultant to a number of start-up companies in diagnostics, devices and healthcare delivery. From 2006-2009, he served as the Chief Medical Officer, Global Medical Affairs and Clinical Strategy, for GE Healthcare, responsible for strategies and operations related to clinical research and trials, protection of patient safety, and medical communication to providers and governments. Dr. Honigberg held the position of Chief Medical Officer and Vice President, Medical and Clinical Affairs at Ethicon Endo-Surgery, a Johnson & Johnson operating company, from 1999-2006.

Prior to that, Dr. Honigberg directed clinical trials, medical affairs operations and strategy for Ortho Biotech and Schering-Plough. Dr. Honigberg is trained as a surgeon and graduated from Duke University with a BA in Economics, obtained his Medical Degree from Northwestern University’s Feinberg School of Medicine, and later an MBA from Northwestern University’s Kellogg School of Management. He undertook his surgical internship and residency at Albert Einstein College of Medicine/Montefiore Medical Center in New York City.

 

 

Mark Kirtland
Vice President, Marketing and Business Development

Mr. Kirtland has served as our Vice President of Strategy and Business Development since July 2010. From August 2006 to May 2010, he served as senior vice president of business development at OraSure Technologies, a developer of point-of-care HIV testing. From 2005 to 2006, Mr. Kirtland was with Valeo Medical, a diagnostic company, as vice president of commercial operations. From 1998 to 2005, he was with Cytyc Corporation (now Hologic), a medical equipment and device company targeting women’s health and cancer. Earlier in his career, Mr. Kirtland worked at Wyeth (now Pfizer) from 1992 to 1997 as a senior product manager and product director and was a management consultant from 1988 to 1992 with McKinsey & Company. Mr. Kirtland received a B.S. degree in biology from Christian Brothers University and an M.S. degree in bioengineering from Columbia University.

 

 

Lucy G. Martindale
Executive Vice President and Chief Financial Officer

Ms. Martindale has served as our Executive Vice President and Chief Financial Officer since 2001. From 1996 to 2001, she served as Vice President and Finance Director of GlaxoWellcome Research & Development, a pharmaceutical research and development company. Ms. Martindale held various positions with GlaxoWellcome, Inc., a pharmaceutical company, from 1984 to 1996, including vice president, corporate planning and analysis. Prior to joining Glaxo, Ms. Martindale worked at Bristol-Myers Squibb, a pharmaceutical company, and American Hospital Supply Corporation, a supplier of hospital equipment and products. Ms. Martindale received a B.S. degree in business from Indiana University and an M.B.A. degree from Campbell University.

 

 

E. Duffy McDonald
Vice President, Operations

Mr. McDonald has served as our Vice President of Operations since 2008 and was our Vice President of Human Resources from 2003 to 2008. From 1994 to 2003, he served as vice president of organizational solutions for the Newton Instrument Company. From 1991 to 1994, he served as director of human resources for VDO–Yazaki Corporation. From 1976 to 1991, he was with Minnesota Mining and Manufacturing Company (3M), where he held several management positions. Mr. McDonald received a B.S. degree in sociology from the College of Charleston. Mr. McDonald is a certified Senior Professional in Human Resources.

 

 

James D. Otvos, Ph.D.
Founder, Executive Vice President and Chief Scientific Officer

Dr. Otvos is a founder of our company and has served as our Chief Scientific Officer since its inception. He has also served as Executive Vice President since 1999 and as a member of our board of directors until March 2011. From 1990 to 2000, Dr. Otvos was a professor of biochemistry at North Carolina State University, where he is currently an adjunct professor. Dr. Otvos received a Ph.D. degree in comparative biochemistry from the University of California-Berkeley and performed his postdoctoral training in molecular biophysics at Yale University.

 

 

Paul C. Sanders
Vice President, Global Sales

Mr. Sanders has served as our Vice President of Sales and Marketing since February 2008. From 2006 to 2008, Mr. Sanders was vice president of sales for the cardio-peripheral division at ev3, Inc., an endovascular technology company. From 2000 to 2006, he held several sales, marketing and management positions, including director of marketing and director of sales at Abbott Vascular Devices, director of marketing for the Spine & Neuro Division of Sofamor Danek (a Medtronic company), several positions in sales and marketing at Boston Scientific, and several sales and management positions at U.S. Surgical. Mr. Sanders received a B.S. degree from the University of North Carolina at Chapel Hill.

 

 

Timothy J. Williams
Vice President, General Counsel and Secretary

Mr. Williams has served as our Vice President, General Counsel and Secretary since 2002. From 1995 to 2001, he served as vice president, associate general counsel and assistant secretary of Glaxo Wellcome Inc. Before joining Glaxo, Mr. Williams was in private practice. He received a B.A. degree from Carleton College, a J.D. degree from the University of California-Berkeley and an M.B.A. degree from the Fuqua School of Business at Duke University.

LipoScience holds an annual summit of thought leaders in the fields of diabetes and cardiovascular disease prevention where thoughts, ideas, and new data regarding the diagnosis and management of cardiovascular disease are shared.

 

H. Bryan Brewer, Jr. M.D.
Washington Cardiovascular Associates
Senior Research Consultant
Lipoprotein and Atherosclerosis Research
Cardiovascular Research Institute
MedStar Research Institute

 

John B. Buse, M.D. Ph.D.
Professor of Medicine
Chief, Division of Endocrinology
Director, Diabetes Care Center
University of North Carolina School of Medicine

 

Michael Davidson, M.D.
Executive medical Director & Founder
Radiant Research
Clinical Professor and Director of Preventive Cardiology
The University of Chicago

 

Richard Kahn, Ph.D.
Independent Consultant and Researcher
Alexandria, VA.

 

Peter O. Kwiterovich, M.D.
Chief, Lipid Research/Atherosclerosis Unit Director
University Lipid Clinic Professor of Pediatrics
Professor of Medicine, The Johns Hopkins University School of Medicine

 

Daniel J. Rader, M.D.
Norman and Elizabeth McLure Professor of Medicine and Pharmacology

 

Robert S. Rosenson, M.D., F.A.C.C
Professor of Medicine at the Mount Sinai School of Medicine where he serves as Director of Cardiometabolic Disorders, New York, NY.

 

Richard F. Wright, M.D.
Research Director and Director, Heart Failure Center, Pacific Heart Institute
Co-Director, Medicare Contractor Advisory Committee for California
Vice-Chair, American College of Cardiology National Carrier Advisory Committee
Past-President and Governor, California Chapter, American College of Cardiology